Research team confirms safety of Alzheimer's drug Lecanemab

Eisai's Alzheimer's drug Lecanemab, also known as Leqembi
| GETTY IMAGES / VIA BLOOMBERG
Threads
Email
Print
Bookmark story
Copy link
More than 90% of patients receiving Alzheimer's drug Lecanemab in hospitals across Japan have been able to continue treatment without strong side effects, a group of researchers has said.Lecanemab, developed by Eisai and Biogen and put on sale in December 2023, removes amyloid beta from the brain to slow the progress of Alzheimer's disease.The research team examined data on the health status of 2,672 patients 28 weeks after the start of the treatment that was collected by Eisai, a Japanese drugmaker, by early July last year.About 60% of the patients, age 76 on average, had symptoms of mild cognitive impairment, according to the researchers including Atsushi Iwata of Tokyo Metropolitan Institute for Geriatrics and Gerontology.The survey showed that while 7.1% of the patients experienced side effects such as small amounts of bleeding, serious side effects were observed in only 0.1%.Some 17% of the patients had a fever or a headache but their conditions improved in a couple of days.The survey found that 7.3% of the patients had discontinued the treatment as of 28 weeks.Iwata said that the safety of Lecanemab was confirmed at actual clinical practices
The team will conduct a follow-up survey of up to three years to examine the drug's effectiveness.

KEYWORDS
Alzheimer's(https://www.japantimes.co.jp/tag/alzheimers), drugs(https://www.japantimes.co.jp/tag/drugs), health(https://www.japantimes.co.jp/tag/health)
In a time of both misinformation and too much information, quality journalism is more crucial than ever.By subscribing, you can help us get the story right.

SUBSCRIBE NOW
With your current subscription plan you can comment on stories
However, before writing your first comment, please create a display name
in the Profile section of your subscriber account page.

Your subscription plan doesn't allow commenting
The human-made roots of Japan's hay fever crisis
Japan’s residency debate risks turning integration into exclusion
Average cherry blossom-viewing budget falls 13.8%
Japan calls GSDF officer’s break-in at Chinese Embassy ‘deeply regrettable’
Malinin seeks post-Olympics redemption at world championships in Prague
What you need to know about Japan’s new joint custody system
Spring reawakens concerns over bear encounters in Japan
1 fan also happens to be the owner
Takaichi weathers Trump, but China challenges linger
For Suda51, punk in games isn’t dead
Beijing row highlights need for Japan to reduce cleantech dependence on China
Kabukicho: Tokyo’s ‘stadium of desire’
Inaka no Taiho: Chinese restaurant offers experience of ‘receiving life’
Sponsored contents planned and edited by JT Media Enterprise Division.

Failure to secure Red Sea shipping casts shadow over Strait of Hormuz plan
59 mins ago
Former Tokyo police officer found guilty of leak to sex scout group
1 hour ago
Takaichi asks IEA chief to prepare additional 'coordinated release' of oil
1 hour ago
CIC's Tim Rowe suggests more policy support for Japanese startups
1 hour ago
Trump sends peace plan as Iran opens to 'non-hostile' oil vessels
1 hour ago